The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Mar. 11, 1997
Filed:
Sep. 27, 1994
Luc Montagnier, Le Plessis Robinson, FR;
Bernard Krust, Paris, FR;
Solange Chamaret, Paris, FR;
Francois Clavel, Paris, FR;
Jean-Claude Chermann, Elancourt, FR;
Francoise Barre-Sinoussi, Issy les Moulineaux, FR;
Abstract
A novel human retrovirus which is the aetiological agent of acquired immune deficiency syndrome (AIDS), designated lymphadenopathy-associated virus (LAV), was isolated from the lymph nodes of a patient suffering from generalized persistant lymphadenopathy. LAV displays a tropism for CD4.sup.+ lymphocytes, a Mg.sup.2+ -dependent reverse transcriptase (RT) activity, a density of 1.16-1.17 as determined by sucrose gradient centrifugation, a particle diameter of 139 nm, and a p25 antigen that is immunologically distinct from the HTLV-I/II p24 protein. Radioimmunoprecipitation analysis (RIPA) of .sup.35 S-cysteine-labeled viral or cellular lysates employing patient antisera resulted in the identification of a viral antigen having a molecular weight of 110 kDa. Endoglycosidase treatment of this antigen produces a protein with a molecular weight of 90 kDa. Methods are disclosed for the preparation of hybridomas producing LAV gp110-specific monoclonal antibodies (Mabs). Methods are also disclosed employing these MAbs in the purification of the LAV envelope glycoprotein, gp110.